Prototypical Stressors

Showing 351 to 375 of 853 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

790	Flecainide		553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure
290	Fluconazole	Fluconazole, CAS-RN: 86386-73-4, DTXSID3020627	None
190	flunixin meglumine	Flunixin meglumine, CAS-RN: 42461-84-7, DTXSID1045584	177: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality
231	Fluoroquinolones:		555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
202	Fluoxetine		3 AOPs 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 97: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
558	Flusilazole	Flusilazole, CAS-RN: 85509-19-9, DTXSID3024235	None
137	Flutamide	Flutamide, CAS-RN: 13311-84-7, DTXSID7032004	4 AOPs 345: Androgen receptor (AR) antagonism leading to decreased fertility in females 306: Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring 344: Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring 477: Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring
203	Fluvoxamine	Fluvoxamine, CAS-RN: 54739-18-3, DTXSID2044002	2 AOPs 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
596	Folpet	Folpet, CAS-RN: 133-07-3, DTXSID0021385	360: Chitin synthase 1 inhibition leading to mortality
672	Food deprivation		None
659	Formaldehyde	Formaldehyde, CAS-RN: 50-00-0, DTXSID7020637	None
810	Forskolin		558: Phosphodiesterase inhibition leading to heart failure
174	Fulvestrant	Fulvestrant, CAS-RN: 129453-61-8, DTXSID4022369	165: Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse
745	Fumonisin B1	Fumonisin B1, CAS-RN: 116355-83-0, DTXSID6020644	449: Ceramide synthase inhibition leading to neural tube defects
626	fungi		None
552	furan	Furan, CAS-RN: 110-00-9, DTXSID6020646	None
157	Gabapentin	Gabapentin, CAS-RN: 60142-96-3, DTXSID0020074	None
273	Gamma radiation		9 AOPs 216: Deposition of energy leading to population decline via DNA strand breaks and follicular atresia 238: Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis 299: Deposition of energy leading to population decline via DNA oxidation and follicular atresia 311: Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis 386: Deposition of ionizing energy leading to population decline via inhibition of photosynthesis 387: Deposition of ionising energy leading to population decline via mitochondrial dysfunction 388: Deposition of ionising energy leading to population decline via programmed cell death 396: Deposition of ionizing energy leads to population decline via impaired meiosis 330: Excessive reactive oxygen species production leading to mortality (4)
757	GANT 58		491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
756	GANT61	GANT61, CAS-RN: 500579-04-4, DTXSID50329591	491: Decrease, GLI1/2 target gene expression leads to orofacial clefting
710	Geldanamycin	Geldanamycin, CAS-RN: 30562-34-6, DTXSID7042691	None
208	Gemfibrozil	Gemfibrozil, CAS-RN: 25812-30-0, DTXSID0020652	2 AOPs 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone
76	Genistein	Genistein, CAS-RN: 446-72-0, DTXSID5022308	167: Early-life estrogen receptor agonism leading to endometrial adenosquamous carcinoma via promotion of sine oculis homeobox 1 progenitor cells
328	Gentamicin	Gentamicin, CAS-RN: 1403-66-3, DTXSID5034642	257: Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity
517	Gevokizumab		None